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Abstract 
The metabolic switch associated with the reprogramming of somatic cells to pluripotency has 
received increasing attention in recent years. However, the impact of mitochondrial and 
metabolic modulation on stem cell differentiation into neuronal/glial cells and related brain 
disease modeling still remains to be fully addressed. Here, we seek to focus on this aspect by 
first addressing brain energy metabolism and its inter-cellular metabolic 
compartmentalization. We then review the findings related to the mitochondrial and metabolic 
reconfiguration occurring upon neuronal/glial specification from pluripotent stem cells 
(PSCs). Finally, we provide an update of the PSC-based models of mitochondria-related brain 
disorders and discuss the challenges and opportunities that may exist on the road to develop a 
new era of brain disease modeling and therapy.  
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Mitochondrial remodeling in cell fate specification 
The majority of cellular energy in form of ATP is provided through oxidative 
phosphorylation (OXPHOS) by mitochondria. Mitochondria are also involved in the 
metabolism of amino acids, fatty acids, and steroids, and contribute to cell signaling through 
the modulation of reactive oxygen species (ROS), calcium homeostasis, and apoptosis [1]. 
Furthermore, intermediate metabolites can cross-talk to the nucleus acting as epigenetic 
regulators [2]. 
In low oxygen environments, a typical conversion process of 1 molecule of glucose 
results into 2 molecules of ATP through glycolysis in the cytosol, which terminates with the 
secretion of lactate into the extracellular environment. Under normoxic conditions, the 2 
molecules of pyruvate, generated through glycolysis, can enter the mitochondria and undergo 
further oxidation in the tricarboxylic acid (TCA) cycle, leading to the production of additional 
34 molecules of ATP [3]. However, under conditions requiring high proliferative rates, this 
mitochondrial-based energy generation may be shut-down despite the presence of normal 
oxygen concentration [4]. This situation, known as aerobic glycolysis or Warburg effect, was 
first described by Otto Warburg in the context of cancer [5]. Recent studies demonstrated that 
a Warburg-like effect may also represent a defining feature of stem cells [6–8].  
Since distinct cell types have different energy demands, regulation of mitochondria 
may represent an essential process allowing the cells to meet their biological requirements. 
The metabolic identity of cells may in fact be influenced not only by changes in the 
expression of metabolic genes, but also by modulation of mitochondrial dynamics and 
mitochondrial DNA (mtDNA) copy number [9,10]. In particular, energy metabolism is shifted 
towards glycolysis in stem cells, whose mitochondria appear round-shaped with poorly-
developed cristae [11,12]. This is in sharp contrast to cells with high energy demands, like 
muscle cells and neurons, where mitochondria are abundant in number and exhibit tubular-
like morphology and cristae-rich structures [13]. 
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As a consequence, acquisition of a distinct metabotype may also modulate cellular 
identity. Accordingly, dysregulated TCA metabolites, so called oncometabolites, can 
contribute to cancer cell transformation [14,15]. This has also become evident in the process 
of reprogramming somatic cells into induced pluripotent stem cells (iPSCs), where early 
metabolic reconfiguration may dictate the changes in proliferative capabilities and epigenetic 
reconfiguration which ultimately enable the acquisition of a self-renewing pluripotent cellular 
state [16–18]. Indeed, inhibiting mitochondrial function promotes pluripotency [19–22], while 
stimulation of mitochondrial biogenesis induces stem cell differentiation [23–25]. 
Mitochondria are particularly crucial for the functionality of neuronal cells. Neurons 
are highly active post-mitotic cells that rely on localized bioenergetics and calcium buffering 
at presynaptic compartments to allow the firing of action potentials [26,27]. It is therefore not 
surprising that diseases affecting mitochondrial function mainly manifest in form of 
neurological conditions. This is the case for classical mitochondrial disorders, which are 
caused by mutations in the mtDNA [28,29]. Moreover, dysfunctional mitochondria are 
commonly observed in neurodegenerative diseases including Huntington’s disease, 
Parkinson’s disease, and Alzheimer´s diseases [30,31]. 
Here, we review the recent developments in the study of mitochondrial and metabolic 
regulation in the establishment of neuronal identity and provide an overview of the 
mitochondrial-related phenotypes that have been observed using stem cell-based models of 
neurological disorders. 
 
Brain energy metabolism 
Sufficient brain energy supply is probably the most unneglectable task of the human 
body. The human brain consumes up to 20% of total body energy even though it accounts 
only for 2% of the total body weight [32]. It was shown already over 60 years ago that 
glucose is the obligatory energy substrate for the brain, where it is almost fully oxidized [33]. 
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However, some part of glucose entering the brain also yields lactate following aerobic 
glycolysis [34,35].  
At the cellular level, aerobic glycolysis and lactate production are considered to be 
metabolic features of glia cells [36]. In fact, down-regulation of glycolytic genes has been 
found to specifically impair glial physiology [37]. According to the astrocyte-neuron-lactate 
shuttle (ANLS) hypothesis [38], the lactate produced through astrocytic glycolysis is taken up 
by neurons, which can convert it into pyruvate for ATP generation in the mitochondria 
through OXPHOS [37]. The employment of lactate-derived energy generation may allow 
neurons to re-route glucose into the pentose phosphate pathway (PPP), which generates 
nucleotide precursors and contributes to antioxidant defense through the production of 
glutathione [39–42]. 
Oligodendrocytes might also be metabolically coupled to the axonal compartment to 
provide lactate to myelinated axons [36,43]. The same may be true also for Schwann cells, 
which provide peripheral axons with energy-rich metabolites independently from the presence 
of myelin [44]. A recent work of Mächler et al. employed a genetically encoded FRET sensor 
in combination with two-photon microscopy to monitor lactate in vivo, which confirmed the 
presence of a lactate gradient existing between astrocytes and neurons [45].  
The reason underlying this metabolic compartmentalization between neuronal and 
glial cells was originally thought to be related to the morphological features of neurons. The 
long and complex axon extension and branching was believed to require energy-consuming 
transport processes to balance the metabolic costs of impulse conduction and membrane 
repolarization [46]. However, the majority of the energy usage seems to occur locally at the 
level of synapses [47]. On the other hand, the conductance of the action potential through the 
axons has been found to cause only minimal dissipation of energy [48]. The synaptic 
compartment may thus represent the major site of mitochondrial respiration within neurons, 
thereby accommodating its specific expenditure. Mitochondria within synapses may 
 6 
additionally exert a key role of calcium buffering. In fact, tight calcium regulation is critical 
for neuronal firing and its excessive influx may trigger the apoptotic cascade [27,49]. 
Conversely, local glycolysis-derived bioenergetic support may take place within the axons 
[50]. Finally, glycolysis-derived bioenergetics may be important during neurogenesis, early 
neural development, and synaptic plasticity [34,35].  
Other important energy metabolites released from astrocytes to neurons are ketone 
bodies, which are derived from fatty acids [51] or leucine [52]. Under particular conditions, 
such as fasting, uncontrolled diabetes, or maternal milk diet in newborns, ketone bodies are 
responsible for sustaining the energetic requirements of the brain [32]. Astrocytes have also 
an important role in lipid metabolism, and the cholesterol pathway in particular. The central 
nervous system contains 25% of the total-body cholesterol [53]. Brain cholesterol is produced 
in the astrocytic compartment, bound to apolipoprotein E, and eventually carried to the 
neighboring neuronal cells [54].  
Finally, the heterogeneity of mitochondria in the brain is important for ensuring 
correct neuron-astrocyte interactions with respect to nitrogen metabolism, which is connected 
to the glutamine-glutamate-cycle and the antioxidant response via glutathione [55]. Excess 
ammonia is toxic to the central nervous system and its concentration in the brain must be kept 
low. This is accomplished by the high activity of glutamine synthetase, which is localized in 
astrocytes [56] and which permits efficient detoxification of incoming or endogenously 
generated ammonia. On the other hand, glutamine is released from astrocytes to be taken up 
by neurons, where it is converted back to glutamate by the action of glutaminase [57].  
Taken together, brain cells exhibit unique metabolic hallmarks, due to their specific 
biological requirements, morphological properties, and inter-cellular coupling. These features 
need to be taken in consideration for the appropriate generation of neuronal and glial 
derivatives from stem cells and for the development of stem cell-based models of neurological 
disorders (Figure 1). 
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Mitochondrial and metabolic reconfiguration in neuronal/glial commitment 
The differentiation of stem cells into neurons occurs rapidly and globally during the 
development of the nervous system. In the adult brain, neurogenesis can still take place within 
specific brain regions [58,59]. In particular, residual populations of multipotent stem cells 
exist in the subgranular zone of the dentate gyrus in the hippocampus and in the 
subventricular zone of the cortex [60,61]. These multipotent stem cells, defined as neural stem 
cells (NSCs) or neural progenitor cells (NPCs) retain the potential to give rise to the three 
cellular identities comprising the mammalian central nervous system, i.e. neurons, astrocytes, 
and oligodendrocytes.  
The commitment of stem cells towards the neural lineage is accompanied by defined 
chromatin remodeling [62–64]. Accordingly, distinct post-translational histone modifications, 
such as methylation, acetylation, deacetylation, phosphorylation, each occurring at specific 
sites and amino-acid residues, have been associated with specification of neuronal and glial 
cell types [65,66]. Hence, during neural induction, multiple cellular mechanisms need to be 
simultaneously regulated, requiring finely-tuned metabolic adaptations.  
NPCs reside in their niches under hypoxic conditions and therefore have to rely on a 
metabolic state allowing the maintenance of stemness. The transcription factor FoxO3 has 
been found to influence the state of NPCs in vivo and to be necessary for their self-renewal by 
regulating genes involved in oxidative stress response and glucose metabolism [67,68]. 
During neuronal differentiation, a switch towards normoxia occurs, leading to FoxO3 
repression and consequent elevation of ROS levels. Accordingly, increased ROS 
concentrations are believed to prime NPCs for differentiation by activating the eicosanoid 
pathway [69].  
Within NPCs generated in vitro from pluripotent stem cells (PSCs), mitochondrial 
structure and functionality appeared indistinguishable from that of brain-derived NPCs [70]. 
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During neural induction of PSCs into NPCs, globular-like mitochondria convert into  
elongated-like structures with clearly developed cristae and dense matrices [70] [Lorenz et al, 
unpublished]. This is paralleled by an increase in mitochondrial mass and mitochondrial DNA 
content [71]. In addition, the remodeling of mitochondrial morphology during neural 
induction is accompanied by changes in the energy metabolism. Highly proliferative NPCs 
derived from human embryonic stem cells (ESCs) were found to exhibit low ATP turnover 
possibly due to high glycolytic rates [72]. However, our unpublished results suggest that, in 
spite of these low ATP levels, human PSC-derived NPCs rely more on OXPHOS-based 
metabolism and show decreased lactate production and reduced expression of glycolytic 
genes as compared to undifferentiated PSCs (Lorenz et al, unpublished). 
Regulation of mitochondrial biogenesis may also impact neural differentiation. NPCs 
and newly generated neurons have been found to express elevated levels of PGC1a 
(peroxisome proliferator-activated receptor gamma coactivator 1 alpha) [73], which is a 
master regulator of mitochondrial biogenesis [74]. Moreover, knockout of PGC1a in mice 
causes cellular vacuolization in several brain regions [75], further implying PGC1a in the 
dynamic process of neuroplasticity.  
Importantly, neural differentiation and neural development may also be dependent on 
mtDNA integrity. The mitochondrial genome is notably susceptible to oxidative damage due 
to ROS which are common by-products of OXPHOS and concentrate in the mitochondrial 
matrix [76]. Oxidative damage may in turn interfere with mtDNA transcription and 
replication and therefore impact the activity of the electron transport chain (ETC). In fact, 
failure to maintain mtDNA integrity has been found to lead to impaired neuronal maturation 
[77]. Therefore, it is of utter importance to verify the mtDNA sequence during in vitro 
reprogramming and further differentiation into neuronal cells. Using Sanger-based whole 
mtDNA sequencing, we observed that the mitochondrial genome sequence, including 
 9 
individual variants, is entirely retained during iPSC generation from patient fibroblasts as well 
as during the conversion of iPSCs into NPCs (Lorenz et al, unpublished). 
During differentiation of human NPCs into motor neurons, mitochondrial biogenesis is 
elevated while mitochondrial mass remains unchanged [78]. Differentiating cells increase 
their mitochondrial components, leading to enhanced bioenergetic capacity. Hence, the 
generation of motor neurons from NPCs requires ATP synthesis coupling and low glycolytic 
flux [78]. 
Similarly, neuronal differentiation of mouse ESCs into dopaminergic neurons has been 
shown to fail when mitochondrial complex III was inhibited with Antimycin A [20]. 
Following this inhibition, the expression of pluripotency-associated protein OCT4 remained 
elevated and was accompanied by a concomitant increase of HIF1a protein. Therefore, 
blocking mitochondrial respiration may lock stem cells in their glycolysis-dependent 
undifferentiated state, thereby preventing the acquisition of an OXPHOS-dependent neuronal 
identity.  
Brunet et al. (2004) investigated changes in phenotypic and metabolic markers upon 
differentiation of mouse NPCs into astrocytes. Together with the acquisition of glial marker 
expression and associated morphological transformation, the authors observed increased 
expression of the glutamate transporter GLAST and the monocarboxylate transporter MCT1, 
which is needed for appropriate lactate release and is thus in agreement with the ANLS 
hypothesis [79].  
In addition to rapid neuronal differentiation from PSCs [80], mature neurons/glia may 
also be generated through direct conversion from adult/somatic cells [81–83]. This can be 
achieved by forced over-expression of key neuronal/glial-associated transcription factors 
which can enable the conversion of both human and mouse fibroblasts into neurons or 
astrocytes [81,84]. Moreover, astrocytes may also be directly converted into neurons in vivo 
[85]. Importantly, Gascón et al. recently revealed that the starting metabotype of the cells is a 
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key modulator of the direct conversion of mouse fibroblasts and astrocytes into neurons [86]. 
In fact, metabolic restructuring and ectopic expression of the mitochondrial anti-apoptotic 
protein Bcl-2 were found to promote neuronal differentiation. These findings suggest that 
modulation of energy metabolism may represent a central mechanism enabling the acquisition 
of a novel cellular identity not only in the case of reprogramming towards pluripotency or 
differentiation into mature cells, but also during trans-differentiation. Further studies will be 
required to molecularly dissect the mitochondrial and metabolic modifications, and their 
associated epigenetic regulation, taking place during the direct generation of neurons and 
astrocytes from somatic cells. 
 
iPSC-based modeling of brain disorders 
Human diseases associated with mitochondrial impairment commonly cause 
neurological dysfunction. Indeed, although single symptoms may differ, mitochondrial 
disorders mostly affect the nervous system [28]. Mitochondrial disorders are particularly 
challenging since mitochondria are under combined genetic control of both nuclear and 
mitochondrial genome [31,87]. Mutations in either genome may lead to altered function of the 
proteins or RNA molecules residing in the mitochondria directly or indirectly. Furthermore, 
because of the multi-copy nature of mtDNA, the expression and severity of mitochondrial 
disease symptoms may depend on the level of mutation heteroplasmy (amount of mutated 
mtDNA molecules over wild-type molecules). Additionally, there exist a number of 
neurological conditions associated with impaired mitochondrial function, including more 
frequent neurodegenerative disorders such as Huntington’s disease, Parkinson’s disease, and 
Amyotrophic Lateral Sclerosis [88].  
In all these diseases, the modeling systems may not fully recapitulate the human neural 
phenotypes [89]. In fact, given the inaccessibility of the affected human neural cells, the 
advances in understanding the underlying molecular mechanisms are particularly hampered 
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for neurological diseases. This is particularly true for mitochondrial disorders, for which no 
animal model exist and for which cellular models, such as cybrids [90], fail to reproduce the 
metabolism of the susceptible neural cells and the patient-specific nuclear/mitochondrial 
genome match. Hence, the development of novel therapeutic options for mitochondria-
associated neurological diseases is highly needed, together with the establishment of 
innovative strategies to achieve this goal.   
Modeling neurological disorders via iPSCs holds great promise. In the context of 
mitochondrial-related diseases, the most striking property of iPSCs is that they would enable 
the generation of disease-relevant cell types carrying both the mitochondrial and nuclear 
genetic background of the patients. This critical feature would enable the investigation of 
genotype-phenotype correlation within the appropriate cellular environment, thereby allowing 
the dissection of the disease pathways and the specific contribution of neuronal/glial cells in 
the pathogenesis.  
Nonetheless, key challenges and limitations still exist when using patient-specific 
neural cells for the study of brain disorders, as discussed in a recent opinion piece [91]. 
Critical aspects include the derivation of fully mature human neuronal and glial subtypes in a 
cost-effective and time-efficient manner, the achievement of pure populations, and the 
establishment of an in vitro system able to recapitulate the complex brain-specific metabolic 
interplay between the different brain populations. Moreover, epigenetic factors and somatic 
mosaics may add additional layers of complexity that may further hinder successful PSC-
based modeling of brain disorders [91,92] (Figure 1). 
 
iPSC models of mitochondrial neurological diseases 
To date, a few iPSC-based models of mitochondrial DNA disorders have been 
reported. MELAS (Mitochondrial myopathy, Encephalomyopathy, Lactic Acidosis, and 
Stroke-like episodes) [93] was recently investigated using iPSCs. This was accomplished by 
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several groups [93–98]. A common feature identified by these studies was that the original 
heteroplasmy level present in the patient fibroblasts can undergo changes before or during 
reprogramming. This phenomenon may thus lead to mutation-rich and mutation-free iPSC 
lines, as we had previously predicted when we performed whole-mtDNA pyrosequencing of 
control fibroblasts and related control iPSCs [99].  
Importantly, the investigation of MELAS mutation during iPSC differentiation into 
neural-like cells demonstrated impaired mitochondrial dynamics and active complex I 
degradation through an autophagy-mediated mechanism [96]. These data indicate that the 
cellular context may actively modify mtDNA segregation and manifestations, and that 
complex I may be specifically down-regulated within neurons carrying the MELAS-causing 
mtDNA mutation m.3243A>G  [96]. Furthermore, the metabolic defects of NPCs derived 
from mutation-rich MELAS iPSC lines were found to be corrected within NPCs that were 
obtained from mutation-free iPSC lines [97]. This further implies iPSC-based studies as a 
powerful system for dissecting the molecular mechanisms of neural dysfunction associated 
with mtDNA mutations.  
Leigh syndrome (LS), the most detrimental mitochondrial disorders causing infantile 
subacute necrotizing encephalomyelopathy, has also been recently being tackled using PSCs 
[97]. iPSCs derived from patient fibroblasts contained unaltered levels of the homoplasmic 
mutation 8993T>G. Using somatic cell nuclear transfer (SCNT), the authors replaced the 
patient mitochondrial genome and therefore enabled the correction of the metabolic 
phenotype identified in differentiated cells carrying the mutation. This implies that stem cell-
related technologies may not only allow the dissection of disease mechanisms but also 
potentially enable cellular replacement applications using genetically corrected PSC-derived 
cellular progeny.  
A mitochondrial gene replacement technology-based work has also been undertaken in 
the context of Leber´s Hereditary Optic Neuropathy (LHON), which is due to homoplasmic 
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mtDNA mutations in the complex I and causes degeneration of retinal ganglion neurons and 
blindness in young adults [28]. Iyer et al. (2012) introduced LHON pathogenic mutation into 
human ESC-derived NPCs [100]. Further studies using this model for the derivation of 
various neuronal and glial cell types may enable the investigation of disease-associated 
mechanisms. 
Nuclear mutations of mitochondrial proteins may also cause mitochondrial brain 
disorders. Mouse ESCs have been recently generated from blastocysts harboring a deletion of 
the nuclear gene NDUFS4 [101], which encodes for a Complex I protein whose mutation has 
been associated with Leigh syndrome [102]. Interestingly, the generated ESCs displayed 
aberrant gene expression patterns during embryoid body (EB)-based differentiation and 
astrocytes induction. Further detailed analysis using this system may allow identifying the 
bases for the mutation-associated neurological defects. 
Hick et al., (2013) generated iPSCs from patients with Friedreich´s ataxia (FRDA), a 
recessive neurodegenerative disorder caused by expanded GAA trinucleotide repeats within 
the gene encoding for the mitochondrial protein frataxin [103]. Neurons derived from FRDA-
iPSCs recapitulated the characteristic features of the disease terms of GAA expansion as well 
as FRDA instability. Importantly, impaired mitochondrial function could be observed in 
derived neuronal cells, including decreased mitochondrial membrane potential and 
progressive mitochondrial degeneration. Hence, the iPSC system may represent a promising 
tool for advancing the understanding of the mechanisms of action and brain targeting of 
mitochondrial disorders due to both nuclear and mitochondrial mutations.  
 
Mitochondrial impairment in iPSC models of brain disorders 
The mitochondrial state has also been investigated within neuronal cells differentiated 
from iPSCs derived from patients affected by classical neurodegenerative disorders. Cooper et 
al. (2013) analyzed iPSC-derived neural cells carrying mutations in the PINK1 (PTEN-
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induced putative kinase 1) and LRRK2 (leucine-rich repeat kinase 2) genes causing 
Parkinson´s disease (PD) [104]. Interestingly, they observed dysfunctional mitochondrial 
dynamics that could be rescued with coenzyme Q10, rapamycin, or the LRRK2 kinase 
inhibitor GW5074, emphasizing the importance of oxidative stress and mitochondrial 
dysfunction in the pathogenesis of PD. Likewise, Nguyen and the colleagues (2011) showed 
that LRRK2 mutant iPSC-derived midbrain dopaminergic neurons were susceptible to 
oxidative stress [105]. 
The work by Kiskinis et al. (2014), which combined stem cell reprogramming and 
genome engineering, shed light on the mechanisms at the bases of the selective cell death of 
motor neurons in patients with Amyotrophic Lateral Sclerosis (ALS) [106]. In particular, they 
showed that mutant SOD1 iPSC-derived motor neurons exhibited altered mitochondrial 
morphology and motility, suggesting a disruption of the delicate balance between ER 
signaling and neuronal excitability. In accordance, a reduction in voltage-activated sodium 
and potassium currents, which may be linked to deregulated calcium homeostasis, has been 
observed in ALS iPSC-derived motor neurons [107].  
Recently, mitochondrial and metabolic alterations have been also demonstrated in 
iPSC-derived neural cells from patients with Huntington´s disease (HD). In fact, NPCs 
carrying extended CAG repeats displayed disease-associated changes not only in 
electrophysiology and cell adhesion but also in energy metabolism, as shown by decreased 
intracellular ATP content and ATP/ADP ratio [108]. A proteomics-centered study by 
McQuade and colleagues (2014) compared unaffected and affected human HD-ESCs as well 
as terminal differentiated neural cells and found key differences in the expression levels of 
components of ETC complexes as well as loss of NADPH and fatty acid oxidation capacity 
and aberrant mitochondrial dynamics [109].  
Finally, mitochondrial-associated alterations have also been detected in iPSC models 
of neurodevelopmental and psychiatric disorders. Robicksek et al. (2013) investigated iPSCs 
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from patients with schizophrenia and demonstrated that dopaminergic neurons failed to 
differentiate, whereas glutamatergic cells were not able to fully mature [110]. Impaired 
mitochondrial respiration was observed in both neuronal types as well as dissipation of 
mitochondrial membrane potential and disturbances in mitochondrial network structure. 
These mitochondrial phenotypes may possibly contribute to the identified loss of neuronal 
differentiation and connectivity. Accordingly, altered oxygen metabolism has been associated 
to the neurogenesis of iPSCs derived from a schizophrenic patient [111]. Although future 
studies are warranted to address the connection between neural differentiation and 
mitochondrial function in schizophrenia, the studies so far conducted highlight the potential 
that iPSC-based studies may bring to the dissection of the molecular mechanisms underlying 
complex psychiatric disorders.  
 
Conclusion 
Energy metabolism plays a key role in directing cell proliferation, differentiation, and 
reprogramming, as well as on the maintenance of stemness [112–114]. Given the high energy 
demand and the complex distribution of mitochondria in the brain, mitochondrial dysfunction 
can strongly affect neuronal/glial differentiation [77,115]. It is therefore not surprising that 
disturbances in mitochondrial energy metabolism are among the prominent causative factors 
in neurodegenerative and neurodevelopmental disorders.  
Insufficient understanding of brain disease mechanisms may be due to the lack of 
appropriate model systems capable of recapitulating the human brain complex multi-cellular 
metabolic environment. In fact, when compared with other human diseases, such as cardiac-
based dysfunctions, almost no novel therapeutic targets of brain disorders have been 
discovered in the past twenty-five years [116], making neurological diseases a huge burden 
for society.  
 16 
In order to enable a new era of brain disease therapy, stem cell research should aim on 
establishing multi-cellular 3D in vitro systems coupled with nuclear and mitochondrial 
genome targeting that would take into account the specific metabolic features of the cells. 
This may potentially allow the generation of faithful modeling systems which could 
ultimately lead to the discovery of novel therapeutic targets and specific counteracting 
actions. In particular, detailed investigations of the connection between cell fate and 
metabolism should in future provide strategies for targeted differentiation from pluripotent 
stem cells and unveil novel opportunities for metabolic and pharmacological approaches 
against debilitating brain disorders. 
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Figure legend 
 
Figure 1: Stem cell-based modeling of brain disorders 
Pluripotent stem cells (PSCs) mainly rely on glycolytic metabolism and exhibit low rate of 
oxidative phophorylation (OXPHOS), as identified by immature-like fragmented 
mitochondria. Upon conversion into neuronal progenitor cells (NPCs), mitochondrial 
maturation takes place, which is marked by organelle fusion and elongation and increased 
cristae complexity. Simultaneously, the glycolytic rate decreases, giving rise to a cellular 
metabotype mainly dependent on OXPHOS, although to a lower level compared to post-
mitotic neurons. Mature neurons strongly rely on OXPHOS metabolism and utilize astrocyte-
derived lactate for energy production. This leaves glucose neuronal consumption free to be 
employed for redox balance through glutathione generation via the pentose phosphate 
pathway. Glia cells, on the other hand, take up the majority of glucose for glycolytic-based 
energy derivation. This division of labor and metabolic compartmentalization is also reflected 
in the mitochondrial physiology. Neurons display a more complex mitochondrial network, 
especially within the regions with high energy demands like synapses, which also require the 
mitochondrial presence for local calcium buffering. PSC-derived NPCs, neurons and glia may 
serve as excellent models for brain diseases and could represent important platforms for the 
development of innovative treatment strategies. 
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